A separate multiple regression model took into consideration known variables that affect weight loss response to antiobesity medications including age, baseline weight, type 2 diabetes, and nutritional and behavioral support (Table 2, Model 2A)
The current study revealed that plasma ALC levels were approximately 42% lower in individuals with hypercholesterolemia compared to those without hypercholesterolemia
Lillys Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial
Risk appears greater with higher GLP-1 doses and longer treatment duration, and may be more pronounced in those using these medications for weight management rather than diabetes alone, as shown in the 2022 JAMA Internal Medicine meta-analysis
Por otro lado, es importante sealar que algunos comentarios reflejan inquietudes especficas respecto al producto